Efeitos do uso de aspirina na prevenção de pré-eclâmpsia em gestantes de alto risco
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Resumo
Objetivo: Avaliar a eficácia do uso profilático de aspirina na redução da incidência de pré-eclâmpsia em gestantes de alto risco. Métodos: Trata-se de uma revisão integrativa da literatura realizada através das bases PubMED, Biblioteca Virtual em Saúde (BVS) e Periódico CAPES, usando os descritores: ”Aspirin”, “Effects”, “Pre-Eclampsia”, “Prevention” e obtendo o truncamento de pesquisa: (Effects) AND (Aspirin) AND (Prevention) AND (Pre-Eclampsia). Foram encontrados 1.122 artigos, filtrados conforme critérios de inclusão (idiomas português, inglês e espanhol; período de 2019 a 2024; artigos completos) e exclusão (artigos duplicados, resumos, fora do escopo). Resultados: A aspirina é recomendada para melhorar resultados perinatais, especialmente quando iniciada entre 11 e 16 semanas de gestação. No entanto, a adesão ao tratamento é baixa, afetando a eficácia, com até 50% das gestantes não seguindo as recomendações. Fatores como falta de informação e preocupações sobre efeitos adversos contribuem para essa resistência e, embora a aspirina mostre benefícios, ainda há desafios, como a resistência ao tratamento e variações na resposta. Considerações finais: O uso profilático de aspirina é eficaz na redução da pré-eclâmpsia em gestantes de alto risco. No entanto, são necessários estudos adicionais para otimizar o uso da aspirina e maximizar seus benefícios.
##plugins.themes.bootstrap3.article.details##
Copyright © | Todos os direitos reservados.
A revista detém os direitos autorais exclusivos de publicação deste artigo nos termos da lei 9610/98.
Reprodução parcial
É livre o uso de partes do texto, figuras e questionário do artigo, sendo obrigatória a citação dos autores e revista.
Reprodução total
É expressamente proibida, devendo ser autorizada pela revista.
Referências
2. GARCIA-MANAU P. et al. Clinical effectiveness of routine first-trimester combined screening for pre-eclampsia in Spain with the addition of placental growth factor. Acta obstetricia et gynecologica Scandinavica, 2023; 102(12): 1711–1718.
3. GHAZANFARPOUR M. et al. Prophylactic aspirin for preventing pre-eclampsia and its complications: An overview of meta-analyses. Drug discovery today, 2020; 25(8): 1487–1501.
4. GIL-VILLA, A. et al. Role of aspirin-triggered lipoxin A4, aspirin, and salicylic acid in the modulation of the oxidative and inflammatory responses induced by plasma from women with pre-eclampsia. American journal of reproductive immunology, 2020; 83(2): 13207.
5. GUO K. et al. Low-dose aspirin inhibits trophoblast cell apoptosis by activating the CREB/Bcl-2 pathway in pre-eclampsia. Cell cycle (Georgetown, Tex.), 2022; 21(21): 2223–2238.
6. HANTOUSHZADEH S. et al. Aspirin administration from early pregnancy versus initiation after 11 weeks of gestation for prevention of pre-eclampsia in high-risk pregnant women: Study protocol for randomized controlled trial. International journal of reproductive biomedicine (Yazd, Iran), 2024; 22(1): 69–80.
7. HERNANDEZ F. et al. Aspirin resistance in pregnancy is associated with reduced interleukin-2 (IL-2) concentrations in maternal serum: Implications for aspirin prophylaxis for preeclampsia. Pregnancy hypertension, 2024; 37(101131): 101131.
8. HU X. et al. The optimal dosage of aspirin for preventing preeclampsia in high-risk pregnant women: A network meta-analysis of 23 randomized controlled trials. Journal of clinical hypertension (Greenwich, Conn.), 2024; 26(5): 455–464.
9. HUAI J. et al. Preventive effect of aspirin on preeclampsia in high-risk pregnant women with stage 1 hypertension. Journal of clinical hypertension (Greenwich, Conn.), 2021; 23(5): 1060–1067.
10. LAILLER G. et al. Aspirin for the prevention of early and severe pre-eclampsia recurrence: A real-world population-based study. Drugs, 2023; 83(5): 429–437.
11. LAKE E. et al. Obstetric care provider’s knowledge about the use of low dose aspirin for preeclampsia prevention in low and middle income countries: a systematic review and meta-analysis. BMC pregnancy and childbirth, 2024; 24(1): 611.
12. LANDMAN A. et al. Long-term health and neurodevelopment in children after antenatal exposure to low-dose aspirin for the prevention of preeclampsia and fetal growth restriction: A systematic review of randomized controlled trials. Obstetrical & gynecological survey, 2022; 77(6): 328–329.
13. LIU J. et al. Aspirin versus metformin in pregnancies at high risk of preterm pre-eclampsia in China (AVERT): protocol for a multicentre, double-blind, 3-arm randomised controlled trial. BMJ open, 2024; 14(4): 74493.
14. MONTFORT P. et al. Low-dose-aspirin usage among women with an increased preeclampsia risk: A prospective cohort study. Acta Obstet Gynecol Scand, 2020; 99(1): 875–883.
15. MULDOON K. et al. Persisting risk factors for preeclampsia among high-risk pregnancies already using prophylactic aspirin: a multi-country retrospective investigation. The journal of maternal-fetal & neonatal medicine: the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, 2023; 36(1): 2200879.
16. REN Y. et al. Application of low dose aspirin in pre-eclampsia. Frontiers in medicine, 2023; 10(1): 1111371.
17. ROLNIK D. et al. Aspirin for evidence-based preeclampsia prevention trial: effects of aspirin on maternal serum pregnancy-associated plasma protein A and placental growth factor trajectories in pregnancy. American journal of obstetrics and gynecology, 2024; 231(3): 3421-3429.
18. SHANMUGALINGAM R. et al. Factors that influence adherence to aspirin therapy in the prevention of preeclampsia amongst high-risk pregnant women: A mixed method analysis. PloS one, 2020: 15(2): 0229622.
19. SU MT. et al. Aspirin enhances trophoblast invasion and represses soluble fms-like tyrosine kinase 1 production: a putative mechanism for preventing preeclampsia. Journal of hypertension, 2019; 37(12): 2461–2469.
20. TOLCHER M. et al. Low-dose aspirin for preeclampsia prevention: efficacy by ethnicity and race. American journal of obstetrics & gynecology MFM, 2020; 2(4): 100184.
21. VAN MONTFORT P. et al. Low-dose-aspirin usage among women with an increased preeclampsia risk: A prospective cohort study. Acta obstetricia et gynecologica Scandinavica, 2020; 99(7): 875–883.
22. VINOGRADOV R. et al. Aspirin non-response in pregnant women at increased risk of pre-eclampsia. European journal of obstetrics, gynecology, and reproductive biology, 2020; 254(1): 292–297.
23. WALSH SW e STRAUSS JF. The road to low-dose aspirin therapy for the prevention of preeclampsia began with the placenta. International journal of molecular sciences, 2021; 22(13): 6985.
24. WRIGHT D. et al. When to give aspirin to prevent preeclampsia: application of Bayesian decision theory. American journal of obstetrics and gynecology, 2022; 226(2S): S1120–S1125.
25. ZHOU L. et al. Evaluation of impacts of aspirin therapy versus placebo on preeclampsia: An observational study. Heliyon, 2023; 9(9): 19527.